PepGen FY2022 net loss $69.1M, cash $181.8M; Phase 2 trials planned for 2023

PepGen Inc.

Net loss $14.9M in Q4 2022, $69.1M for full year 2022 (vs $27.3M in 2021).
Cash and cash equivalents $181.8M as of Dec 31, 2022; expected to fund operations into early 2025.
R&D expenses $54.1M in FY2022 (vs $19.0M in 2021) driven by PGN-EDO51 and PGN-EDODM1 programs.
Anticipates initiating CONNECT1-EDO51 (Phase 2 open-label) in H1 2023 and CONNECT2-EDO51 (randomized) in H2 2023.
Phase 1 FREEDOM-DM1 trial for myotonic dystrophy type 1 expected to start H1 2023.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

PepGen Inc. reported financial results for the fourth quarter and full year ended December 31, 2022.

Period: the fourth quarter and full year ended December 31, 2022
Result: reported results

Exact text from the filing

PepGen Reports Fourth Quarter and Full Year 2022 Financial Results and Recent Corporate Developments

View on SEC.gov

168 earnings releases filed in the last 30 days. Browse all earnings releases →

PepGen Inc. filing history →

Source: SEC EDGAR

accession 0000950170-23-009480

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.